Issue 6, 2018

Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening

Abstract

Indoleamine 2,3-dioxygenase (IDO), an immune checkpoint, is a promising target for cancer immunotherapy. However, current IDO inhibitors are not approved for clinical use yet; therefore, new IDO inhibitors are still demanded. To identify new IDO inhibitors, we have built naive Bayesian (NB) and recursive partitioning (RP) models from a library of known IDO inhibitors derived from recent publications. Thirteen molecular fingerprints were used as descriptors for the models to predict IDO inhibitors. An in-house compound library was virtually screened using the best machine learning model, which resulted in 50 hits for further enzyme-based IDO inhibitory assays. Consequently, we identified three new IDO inhibitors with IC50 values of 1.30, 4.10, and 4.68 μM. These active compounds also showed IDO inhibitory activities in cell-based assays. The compounds belong to the tanshinone family, a typical scaffold family derived from Danshen (a Chinese herb), the dried root of Salvia miltiorrhiza, which has been widely used in China, Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases. Thus, we discovered a new use for Danshen using machine learning methods. Surface plasmon resonance (SPR) experiments proved that the inhibitors interacted with the IDO target. Molecular dynamic simulations demonstrated the binding modes of the IDO inhibitors.

Graphical abstract: Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening

Supplementary files

Article information

Article type
Research Article
Submitted
21 Dec 2017
Accepted
24 Feb 2018
First published
01 Mar 2018

Med. Chem. Commun., 2018,9, 937-945

Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening

H. Zhang, W. Liu, Z. Liu, Y. Ju, M. Xu, Y. Zhang, X. Wu, Q. Gu, Z. Wang and J. Xu, Med. Chem. Commun., 2018, 9, 937 DOI: 10.1039/C7MD00642J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements